Clinical Trials for Head and Neck Cancer
228 head and neck cancer trials indexed, 118 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Head and Neck Cancer
Head and neck cancer refers to a group of cancers that start in the tissues and organs of the head and neck region. This includes areas such as the throat, larynx (voice box), nose, sinuses, and mouth. These cancers typically develop from squamous cells, which are thin, flat cells lining the moist surfaces inside the head and neck. The underlying biology often involves genetic mutations that cause these cells to grow uncontrollably. Diagnosis usually involves a combination of physical exams, imaging tests like CT or MRI scans, and biopsies where a small tissue sample is taken for analysis under a microscope.
Common symptoms of head and neck cancer can include a persistent sore throat, difficulty swallowing, a lump or sore that does not heal, changes in voice, or unexplained ear pain. These symptoms can vary depending on the exact location of the tumor. The typical age of onset is around 50 to 70 years, but younger people can also be affected. Men are more likely to develop head and neck cancer than women. Key risk factors include tobacco use, heavy alcohol consumption, and infection with human papillomavirus (HPV). Exposure to certain chemicals or prolonged sun exposure to the lips can also increase risk.
Head and neck cancer is important medically and socially because it affects critical functions like speaking, eating, and breathing. It is estimated that over 65,000 new cases are diagnosed in the United States each year. Mortality rates remain significant, with about 14,000 deaths annually. The economic burden is also high due to treatment costs and lost productivity. Early diagnosis and effective treatment can improve outcomes, but many cases are found at advanced stages. This makes ongoing research and awareness essential for better management of the disease.
The Head and Neck Cancer Treatment Landscape
The first-line treatment for head and neck cancer depends on the tumor’s location, size, and stage. Surgery is often the initial step to remove the tumor if it is accessible and operable. Radiation therapy may be used alone or in combination with surgery to target remaining cancer cells. For more advanced cases, chemoradiation, which combines chemotherapy and radiation therapy, is a common approach. This tiered treatment strategy aims to control the cancer locally and reduce the chance of recurrence. Multidisciplinary teams including surgeons, medical oncologists, and radiation oncologists collaborate to design the best plan for each patient.
When the cancer does not respond to first-line treatments or returns, second- and third-line options come into play. These may include targeted therapy and immunotherapy. Targeted therapies focus on specific molecules involved in cancer growth. For example, drugs targeting the epidermal growth factor receptor (EGFR) have been used. Immunotherapy drugs, such as checkpoint inhibitors, help the immune system recognize and attack cancer cells. These treatments offer new options for patients who have limited responses to traditional chemotherapy. However, they are not effective for everyone and may come with their own side effects.
There are still significant gaps in current treatment for head and neck cancer. Certain subgroups of patients, such as those with HPV-negative tumors, tend to have poorer outcomes and respond less well to existing therapies. Resistance to chemotherapy and radiation can develop, limiting long-term success. Side effects from treatment, including difficulty swallowing, dry mouth, and changes in speech, can greatly impact quality of life. Research continues to focus on finding therapies that are more effective, less toxic, and better tailored to individual patients. Clinical trials play a key role in exploring these new possibilities.
Why Clinical Trials Matter for Head and Neck Cancer
Clinical trials offer patients access to new treatments that are not yet widely available. They provide an opportunity to receive closer medical monitoring and expert care during the study period. Participating in a clinical trial also helps contribute to scientific knowledge that may benefit future patients. According to ClinicalTrials.gov, there are currently 228 head and neck cancer clinical trials indexed, with 118 actively recruiting participants. This shows an active research community seeking to improve outcomes for this disease.
It is important to understand the risks involved in clinical trial participation. New treatments may have unknown efficacy and side effects. Some trials include placebo arms or standard treatment comparison groups, which means not all participants receive the experimental therapy. Participation may require more frequent clinic visits, tests, and procedures, which can be time-consuming or inconvenient. Patients should discuss these factors carefully with their healthcare team before enrolling.
The landscape of clinical trial sponsors includes academic institutions, pharmaceutical companies, and cooperative groups that unite multiple centers for research. Each sponsor type plays a role in advancing knowledge and developing new therapies. ClinicalTrials.gov serves as a central registry where patients and providers can find up-to-date information about ongoing trials. This transparency helps patients make informed decisions about potential trial participation and supports recruitment efforts for important studies.
What to Look for in a Head and Neck Cancer Clinical Trial
Clinical trials are divided into four main phases. Phase 1 trials test a new treatment’s safety and the best dose. Phase 2 trials focus on how well the treatment works and further evaluate safety. Phase 3 trials compare the new treatment to the current standard treatment to see which is better. Phase 4 trials happen after a treatment is approved to monitor long-term effects. For head and neck cancer, most trials are in Phase 1, with 74 studies, followed by 65 in Phase 2. There are 21 trials in Phase 3, and 40 trials where the phase is not specified.
Inclusion criteria are the rules that decide who can join a trial. For head and neck cancer, common criteria include age limits, often adults 18 years or older. Trials may require patients to have specific types or stages of cancer, such as locally advanced or metastatic disease. Prior treatments like surgery, radiation, or chemotherapy might affect eligibility. Some trials look for certain biomarkers or genetic features in the tumor. The length of time since diagnosis or last treatment can also matter, ensuring patients are in the right stage of their disease for the study.
Exclusion criteria list conditions or factors that prevent someone from joining a trial. These often include other health problems that could make treatment unsafe or interfere with results. For example, severe heart or lung disease might exclude a patient. Some medications can interact badly with the trial drug, so patients taking those would be excluded. Safety thresholds like blood counts or kidney function levels are also common. These rules help protect patients and make sure the study data is reliable.
Practical considerations are important for patients thinking about joining a trial. Trials can last weeks to months, with regular visits for tests and treatment. Travel to the trial site may be needed, which can be challenging for some patients. It is helpful to ask the research team about the total time commitment, frequency of visits, and support for travel costs. Other good questions include: What are the possible side effects? How will my current treatments be managed? What happens if I want to leave the trial early? Who can I contact if I have concerns during the trial?
Primary Sources and Further Reading
Reliable information is key when learning about head and neck cancer clinical trials. The following sources provide detailed and trustworthy content from respected organizations. They cover treatment options, clinical trial basics, and patient support resources. These websites can help patients and caregivers make informed decisions.
- National Cancer Institute: Head and Neck Cancers
- MedlinePlus: Head and Neck Cancer
- ClinicalTrials.gov: Head and Neck Cancer Trials
- Centers for Disease Control and Prevention: Head and Neck Cancers
Latest Research and Emerging Treatments for Head and Neck Cancer (2026)
Ongoing head and neck cancer research is exploring new drugs and combinations to improve treatment options. One study is testing NBTXR3, a drug activated by radiotherapy, with or without cetuximab for elderly patients with advanced head and neck cancer who cannot tolerate platinum chemotherapy (NCT04892173). NBTXR3 works by enhancing the effects of radiation on cancer cells, potentially making the treatment more effective. This approach aims to improve progression-free survival while maintaining safety for patients who have limited treatment choices.
Other studies focus on immunotherapy combinations like pembrolizumab paired with lenvatinib or petosemtamab. Pembrolizumab is an immune checkpoint inhibitor that helps the body’s immune system recognize and attack cancer cells. Lenvatinib is a targeted therapy that may block signals tumors use to grow. Trials are testing whether adding lenvatinib to pembrolizumab improves response rates and delays disease progression in patients with PD-L1 positive tumors (NCT05523323, NCT04199104). Another study compares pembrolizumab alone to a combination with petosemtamab, an antibody designed to bind to cancer cells and enhance immune response (NCT06525220).
For patients with locally advanced head and neck squamous cell carcinoma, a Phase 3 trial is investigating volrustomig as a sequential therapy after chemoradiotherapy (NCT06129864). Volrustomig is being studied to see if it can help control the disease and improve outcomes by targeting cancer cells that remain after initial treatment. These new drugs for head and neck cancer represent efforts to provide more personalized and effective head and neck cancer treatment options. If successful, such treatments could offer patients better chances to manage their disease with fewer side effects.
Frequently asked questions about Head and Neck Cancer trials
How do I find Head and Neck Cancer clinical trials?
The authoritative source for Head and Neck Cancer clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 228 head and neck cancer studies are currently indexed. You can search by entering "head and neck cancer" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new head and neck cancer trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Head and Neck Cancer trials in?
Across the 228 head and neck cancer trials TrialsAlert indexes, the most common phase is Phase 1. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Head and Neck Cancer clinical trials are currently recruiting?
As of the latest scan, 118 head and neck cancer trials have a "Recruiting" status on ClinicalTrials.gov, out of 228 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting head and neck cancer trial matches their tracked condition.
Stay informed about head and neck cancer research
Get a weekly briefing with the trials that matter most.